| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 1.96B | 14.87 | 378.37 | 33.97% | 29.28% | 21.28% | 2.25% | 0.21 |
| ARGXargenx SE | 50.33B | 813.24 | 63.63 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.48B | 19.76 | 54.89 | 15.54% | 32.78% | 12.61% | 12.75% | 0.65 |
| GLPGGalapagos N.V. | 2.24B | 34.03 | 30.38 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.3B | 84.75 | 20.04 | 6.24% | 21.94% | 7.11% | 3.45% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.84B | 24.17 | -2.33 | -11.08% | -63.71% | 0.12 | ||
| PHATPhathom Pharmaceuticals, Inc. | 1.17B | 14.98 | -2.83 | 80.01% | -186.53% | |||
| ORKAOruka Therapeutics, Inc. | 1.57B | 32.50 | -6.51 | -22.44% | 0.00 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 2.93M | 34.03M | 72.83M | 46.83M | 78.59M | 47.07M |
| Revenue Growth % | - | - | 10.6% | 1.14% | -0.36% | 0.68% | -0.4% |
| Cost of Goods Sold | 205K | 825K | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | 0.28% | - | - | - | - | - |
| Gross Profit | -205K | 2.11M | 34.03M | 72.83M | 46.83M | 78.59M | 47.07M |
| Gross Margin % | - | 0.72% | 1% | 1% | 1% | 1% | 1% |
| Gross Profit Growth % | - | 11.29% | 15.14% | 1.14% | -0.36% | 0.68% | -0.4% |
| Operating Expenses | 21.45M | 45.14M | 80.34M | 173.36M | 208.08M | 244.12M | 308.71M |
| OpEx % of Revenue | - | 15.38% | 2.36% | 2.38% | 4.44% | 3.11% | 6.56% |
| Selling, General & Admin | 3.77M | 7.98M | 18.23M | 36.34M | 43.83M | 55.04M | 63.53M |
| SG&A % of Revenue | - | 2.72% | 0.54% | 0.5% | 0.94% | 0.7% | 1.35% |
| Research & Development | 17.68M | 37.16M | 62.1M | 137.02M | 164.25M | 189.08M | 240.25M |
| R&D % of Revenue | - | 12.66% | 1.82% | 1.88% | 3.51% | 2.41% | 5.1% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 4.92M |
| Operating Income | -21.45M | -42.2M | -46.3M | -100.53M | -161.26M | -165.53M | -261.63M |
| Operating Margin % | - | -14.38% | -1.36% | -1.38% | -3.44% | -2.11% | -5.56% |
| Operating Income Growth % | - | -0.97% | -0.1% | -1.17% | -0.6% | -0.03% | -0.58% |
| EBITDA | -21.25M | -41.38M | -44.54M | -98.13M | -158.28M | -161.97M | -254.26M |
| EBITDA Margin % | - | -14.1% | -1.31% | -1.35% | -3.38% | -2.06% | -5.4% |
| EBITDA Growth % | - | -0.95% | -0.08% | -1.2% | -0.61% | -0.02% | -0.57% |
| D&A (Non-Cash Add-back) | 205K | 825K | 1.76M | 2.4M | 2.98M | 3.56M | 7.37M |
| EBIT | -21.45M | -41.2M | -45.48M | -100.04M | -154.63M | -146.77M | -223.61M |
| Net Interest Income | 0 | 959K | 711K | 313K | 6.45M | 18.57M | 37.78M |
| Interest Income | 0 | 1M | 826K | 488K | 6.62M | 18.76M | 38.03M |
| Interest Expense | 16K | 46K | 115K | 175K | 176K | 196K | 249K |
| Other Income/Expense | -16K | 959K | 711K | 313K | 6.45M | 18.57M | 37.78M |
| Pretax Income | -21.47M | -41.25M | -45.59M | -100.22M | -154.81M | -146.96M | -223.86M |
| Pretax Margin % | - | -14.06% | -1.34% | -1.38% | -3.31% | -1.87% | -4.76% |
| Income Tax | 43.86K | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -21.47M | -41.29M | -45.59M | -100.22M | -154.81M | -146.96M | -223.86M |
| Net Margin % | - | -14.07% | -1.34% | -1.38% | -3.31% | -1.87% | -4.76% |
| Net Income Growth % | - | -0.92% | -0.1% | -1.2% | -0.54% | 0.05% | -0.52% |
| Net Income (Continuing) | -21.47M | -41.25M | -45.59M | -100.22M | -154.81M | -146.96M | -223.86M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.48 | -0.93 | -0.99 | -2.09 | -2.87 | -2.52 | -2.98 |
| EPS Growth % | - | -0.94% | -0.06% | -1.11% | -0.37% | 0.12% | -0.18% |
| EPS (Basic) | -0.48 | -0.93 | -0.99 | -2.09 | -2.87 | -2.52 | -2.98 |
| Diluted Shares Outstanding | 44.53M | 44.53M | 44.56M | 47.99M | 53.93M | 58.37M | 75.04M |
| Basic Shares Outstanding | 44.53M | 44.53M | 44.56M | 47.99M | 53.93M | 58.37M | 75.04M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 41.79M | 92.84M | 302.34M | 451.27M | 419.42M | 405.32M | 510.27M |
| Cash & Short-Term Investments | 41.26M | 91.96M | 296.2M | 442.42M | 407.17M | 374.88M | 488.74M |
| Cash Only | 41.26M | 76.02M | 31M | 47.98M | 68.39M | 109.97M | 120.26M |
| Short-Term Investments | 0 | 15.94M | 265.2M | 394.44M | 338.77M | 264.92M | 368.49M |
| Accounts Receivable | 148K | 0 | 1.43M | 135K | 2.54M | 18.76M | 947K |
| Days Sales Outstanding | - | - | 15.37 | 0.68 | 19.78 | 87.14 | 7.34 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 9.71M | 11.67M | 20.58M |
| Total Non-Current Assets | 2.44M | 23.86M | 184.84M | 154.63M | 183.72M | 170.44M | 467.77M |
| Property, Plant & Equipment | 2.24M | 22.08M | 20.69M | 21.31M | 22.24M | 101.08M | 97.86M |
| Fixed Asset Turnover | - | 0.13x | 1.65x | 3.42x | 2.11x | 0.78x | 0.48x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 199K | 0 | 162.53M | 125.19M | 152.33M | 61.43M | 362.16M |
| Other Non-Current Assets | 0 | 1.77M | 1.62M | 8.14M | 9.15M | 7.93M | 7.74M |
| Total Assets | 44.23M | 116.7M | 487.18M | 605.9M | 603.13M | 575.76M | 978.03M |
| Asset Turnover | - | 0.03x | 0.07x | 0.12x | 0.08x | 0.14x | 0.05x |
| Asset Growth % | - | 1.64% | 3.17% | 0.24% | -0% | -0.05% | 0.7% |
| Total Current Liabilities | 4.69M | 34.57M | 110.62M | 92.54M | 71.34M | 85.69M | 67.77M |
| Accounts Payable | 2.06M | 3.28M | 4.37M | 4M | 4.33M | 7.08M | 5.99M |
| Days Payables Outstanding | 3.66K | 1.45K | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 1.31M | 0 | 106K | 228K | 303K | 23.16M | 35.09M |
| Current Ratio | 8.92x | 2.69x | 2.73x | 4.88x | 5.88x | 4.73x | 7.53x |
| Quick Ratio | 8.92x | 2.69x | 2.73x | 4.88x | 5.88x | 4.73x | 7.53x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 73.98M | 156.54M | 92.67M | 53.73M | 41.64M | 95.1M | 74.65M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 393K | 17.82M | 14.73M | 14.36M | 13.39M | 78.33M | 74.65M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 73.59M | 109.08M | 100K | 66K | 248K | 0 | 0 |
| Total Liabilities | 78.67M | 191.11M | 203.29M | 146.27M | 112.98M | 180.79M | 142.42M |
| Total Debt | 695K | 21.19M | 17.99M | 17.96M | 17.34M | 84.67M | 87.76M |
| Net Debt | -40.56M | -54.82M | -13.01M | -30.01M | -51.06M | -25.29M | -32.49M |
| Debt / Equity | - | - | 0.06x | 0.04x | 0.04x | 0.21x | 0.11x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -1340.69x | -917.50x | -402.64x | -574.46x | -916.23x | -844.54x | -1050.74x |
| Total Equity | -34.44M | -74.41M | 283.89M | 459.64M | 490.15M | 394.97M | 835.62M |
| Equity Growth % | - | -1.16% | 4.82% | 0.62% | 0.07% | -0.19% | 1.12% |
| Book Value per Share | -0.77 | -1.67 | 6.37 | 9.58 | 9.09 | 6.77 | 11.14 |
| Total Shareholders' Equity | -34.44M | -74.41M | 283.89M | 459.64M | 490.15M | 394.97M | 835.62M |
| Common Stock | 0 | 0 | 4K | 5K | 6K | 6K | 7K |
| Retained Earnings | -35.21M | -76.46M | -128.76M | -228.98M | -383.79M | -530.75M | -754.61M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 6K | -128K | -660K | -4.95M | -552K | -1.49M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -17.86M | 17.91M | 88.13M | -128.95M | -153.09M | -102.83M | -194.5M |
| Operating CF Margin % | - | 6.1% | 2.59% | -1.77% | -3.27% | -1.31% | -4.13% |
| Operating CF Growth % | - | 2% | 3.92% | -2.46% | -0.19% | 0.33% | -0.89% |
| Net Income | -21.47M | -41.25M | -45.59M | -100.22M | -154.81M | -146.96M | -223.86M |
| Depreciation & Amortization | 205K | 825K | 1.76M | 2.4M | 2.98M | 3.56M | 7.37M |
| Stock-Based Compensation | 648K | 1.2M | 5.19M | 24.97M | 35.48M | 43.12M | 55.01M |
| Deferred Taxes | 0 | 0 | 1.57M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 443K | 54.34M | 332K | 5.83M | 889K | -11.8M | -9.06M |
| Working Capital Changes | 2.31M | 2.79M | 124.87M | -61.92M | -37.62M | 9.25M | -23.97M |
| Change in Receivables | -148K | 0 | -577K | 577K | -2.4M | -16.23M | 17.82M |
| Change in Inventory | 0 | 0 | 6.88M | 8.71M | 2.4M | 0 | 0 |
| Change in Payables | 824K | 0 | 990K | 54K | 253K | 0 | -307K |
| Cash from Investing | -1.36M | -16.49M | -422.59M | -99.83M | 20.52M | 139.89M | -404.08M |
| Capital Expenditures | -1.36M | -532K | -9.1M | -1.6M | -2.84M | -34.48M | -12.84M |
| CapEx % of Revenue | - | 0.18% | 0.27% | 0.02% | 0.06% | 0.44% | 0.27% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | -15.95M | -413.49M | -5.81M | 20.52M | 174.37M | 13.98M |
| Cash from Financing | 52.93M | 34.91M | 289.26M | 250.28M | 153M | 4.19M | 608.85M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 0 | 35.28M | 162K | 8.02M | 4.3M | 4.27M | 13.81M |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -19.22M | 17.37M | 79.03M | -130.54M | -155.92M | -137.31M | -207.34M |
| FCF Margin % | - | 5.92% | 2.32% | -1.79% | -3.33% | -1.75% | -4.4% |
| FCF Growth % | - | 1.9% | 3.55% | -2.65% | -0.19% | 0.12% | -0.51% |
| FCF per Share | -0.43 | 0.39 | 1.77 | -2.72 | -2.89 | -2.35 | -2.76 |
| FCF Conversion (FCF/Net Income) | 0.83x | -0.43x | -1.93x | 1.29x | 0.99x | 0.70x | 0.87x |
| Interest Paid | 0 | 46K | 0 | 0 | 0 | 162K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -43.53% | -26.96% | -32.6% | -33.21% | -36.38% |
| Return on Invested Capital (ROIC) | - | - | -49.03% | -21.53% | -27.84% | -30.7% | -33.46% |
| Gross Margin | - | 71.88% | 100% | 100% | 100% | 100% | 100% |
| Net Margin | - | -1407.36% | -133.96% | -137.6% | -330.6% | -186.99% | -475.57% |
| Debt / Equity | - | - | 0.06x | 0.04x | 0.04x | 0.21x | 0.11x |
| Interest Coverage | -1340.69x | -917.50x | -402.64x | -574.46x | -916.23x | -844.54x | -1050.74x |
| FCF Conversion | 0.83x | -0.43x | -1.93x | 1.29x | 0.99x | 0.70x | 0.87x |
| Revenue Growth | - | - | 1059.99% | 114% | -35.71% | 67.84% | -40.11% |
Kymera Therapeutics, Inc. (KYMR) reported $43.7M in revenue for fiscal year 2024.
Kymera Therapeutics, Inc. (KYMR) saw revenue decline by 40.1% over the past year.
Kymera Therapeutics, Inc. (KYMR) reported a net loss of $295.1M for fiscal year 2024.
Kymera Therapeutics, Inc. (KYMR) has a return on equity (ROE) of -36.4%. Negative ROE indicates the company is unprofitable.
Kymera Therapeutics, Inc. (KYMR) had negative free cash flow of $230.2M in fiscal year 2024, likely due to heavy capital investments.